Precigen Inc PGEN:NASDAQ

Last Price$2.81NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.78 (20)
Ask (Size)$2.80 (26)
Day Low / HighN/A - N/A
Volume1.8 M

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Precigen Inc ( NASDAQ )

Price: $2.81
Change: -0.15 (5.07%)
Volume: 1.8 M
4:00PM ET 1/21/2022

Vaxart Inc ( NASDAQ )

Price: $4.80
Change: -0.25 (5.05%)
Volume: 4.0 M
4:00PM ET 1/21/2022

Kezar Life Sciences Inc ( NASDAQ )

Price: $12.30
Change: -0.02 (0.16%)
Volume: 563.1 K
4:00PM ET 1/21/2022

Rapt Therapeutics Inc ( NASDAQ )

Price: $21.00
Change: -0.65 (3.00%)
Volume: 398.7 K
4:00PM ET 1/21/2022

Bionano Genomics Inc ( NASDAQ )

Price: $2.15
Change: -0.14 (6.11%)
Volume: 10.5 M
4:00PM ET 1/21/2022

Read more news Recent News

Insider Buy: Precigen
5:06PM ET 11/30/2021 MT Newswires

Harry Thomasian Jr., Chief Financial Officer, on November 26, 2021, executed a purchase for 26,500 shares in Precigen (PGEN) for $100,831. Following the...

Insider Buy: Precigen
6:00AM ET 11/24/2021 MT Newswires

Randal J Kirk, 10% Owner, Director, on November 19, 2021, executed a purchase for 1,000,000 shares in Precigen (PGEN) for $3,634,787. Following the Form 4...

Precigen Gets FDA Nod to Begin Early-Stage PRGN-3007 Trial in Hematological, Solid Tumors
1:54PM ET 10/26/2021 MT Newswires

Precigen (PGEN) said Tuesday that the US Food and Drug Administration has approved its investigational new drug application to initiate the phase 1/1b test...

Precigen Appoints CFO
10:16AM ET 10/12/2021 MT Newswires

Precigen (PGEN) said Tuesday that Harry Thomasian Jr. was named as its new CFO effective Oct. 18. Thomasian served most recently as senior client services...

Company Profile

Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
Address20374 Seneca Meadows Parkway
Germantown, Maryland 20876
Number of Employees882
Recent SEC Filing01/06/20224
President, Chief Executive Officer & DirectorHelen Sabzevari
Head-Operations & PortfolioRutul R. Shah
Chief Financial OfficerHarry Thomasian
Chief Science OfficerThomas David Reed

Company Highlights

Price Open$3.00
Previous Close$2.96
52 Week Range$2.80 - 9.89
Market Capitalization$580.9 M
Shares Outstanding206.7 M
SectorHealth Technology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.66
Beta vs. S&P 500N/A
Revenue$160.6 M
Net Profit Margin-73.45%
Return on Equity-54.62%

Analyst Ratings as of 02/24/2021

Consensus RecommendationConsensus Icon
Powered by Factset